Valion Bio (VBIO)
NASDAQ:VBIO
Want to see VBIO full AI Analyst Report?
VBIO Stock Chart & Stats
$1.38
>-$0.01(-2.18%)
At close: 4:00 PM EST
$1.38
>-$0.01(-2.18%)
Day’s Range― - ―
52-Week Range$0.57 - $5.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)99.84K
Market Cap
$1.92M
Enterprise Value$51.51M
Total Cash (Recent Filing)$1.28M
Total Debt (Recent Filing)$500.00K
Price to Earnings (P/E)3.0
Beta1.37
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding3,200,824
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)17.36
Price to Sales (P/S)197.61
P/FCF Ratio-41.06
Enterprise Value/Market Cap26.83
Enterprise Value/Revenue30.40
Enterprise Value/Gross Profit-268.66
Enterprise Value/Ebitda-21.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported zero debt in 2024–2025 materially reduces bankruptcy and interest-service risk, preserving balance-sheet flexibility. Over a 2–6 month horizon this low leverage supports survival through weak operations and provides optionality to raise structured financing or equity on more favorable terms if needed.
ClearUP Product FocusA focused, differentiated consumer bioelectronic product with direct-to-consumer and retail channel potential gives a clear go-to-market model. Durable fundamentals include accessory and repeat purchase opportunities and potential distributor or licensing partnerships that can create recurring revenue streams over the medium term.
Improving Cash BurnA large reduction in operating cash outflows suggests operational adjustments or cost controls are taking effect. If sustained, this trend reduces near-term external funding needs, lengthens runway, and indicates a pathway toward stabilization of operations over the next several months.
Bears Say
Declining RevenueA multi-year revenue decline signifies weakening demand and loss of scale, which undermines gross margin recovery and operating leverage. Over 2–6 months this constrains resource allocation for marketing, R&D, and distribution, making it harder to rebuild market position without material new investment or a strategic commercial shift.
Capital ErosionSevere depletion of assets and equity removes a financial cushion and raises structural solvency risk. This erosion limits the company's ability to invest in commercialization or product improvements and increases reliance on external funding, which may be difficult or dilutive if performance does not improve.
Persistent Cash Burn & LossesDeep, persistent negative EBITDA and continued negative operating/free cash flow imply ongoing financing needs and potential dilution. Without a clear path to sustained positive cash generation, the business faces constrained reinvestment capacity and elevated execution risk over the medium term.
Valion Bio News
VBIO FAQ
What was Valion Bio’s price range in the past 12 months?
Valion Bio lowest stock price was $0.57 and its highest was $5.60 in the past 12 months.
What is Valion Bio’s market cap?
Valion Bio’s market cap is $1.92M.
When is Valion Bio’s upcoming earnings report date?
Valion Bio’s upcoming earnings report date is Aug 17, 2026 which is in 66 days.
How were Valion Bio’s earnings last quarter?
Valion Bio released its earnings results on May 14, 2026. The company reported -$2.151 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.151.
Is Valion Bio overvalued?
According to Wall Street analysts Valion Bio’s price is currently Overvalued.
Does Valion Bio pay dividends?
Valion Bio does not currently pay dividends.
What is Valion Bio’s EPS estimate?
Valion Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valion Bio have?
Valion Bio has 3,200,824 shares outstanding.
What happened to Valion Bio’s price movement after its last earnings report?
Valion Bio reported an EPS of -$2.151 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.376%.
Which hedge fund is a major shareholder of Valion Bio?
Currently, no hedge funds are holding shares in VBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valion Bio
Vitality Biopharma, Inc. specializes in creating cannabinoid-based pharmaceuticals, primarily focusing on addressing inflammatory disorders within the United States. Its current pipeline includes tetrahydrocannabinol glycoside, identified as VBX-100, an orally administered cannabinoid prodrug engineered to combat inflammatory bowel disease (IBD) and irritable bowel syndromes (IBS). Established in 2007, the company originally operated as Stevia First Corp. before officially rebranding as Vitality Biopharma, Inc. in July 2016. Its corporate headquarters are situated in Los Angeles, California.
VBIO Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
2.29% Insiders
0.35% Mutual Funds
1.85% Other Institutional Investors
95.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---